Clinical Outcome after Everolimus-Eluting Stent Implantation for Small Vessel Coronary Artery Disease: XIENCE Asia Small Vessel Study
- Author:
Doo Sun SIM
1
;
Dae Young HYUN
;
Young Joon HONG
;
Ju Han KIM
;
Youngkeun AHN
;
Myung Ho JEONG
;
Sang Rok LEE
;
Jei Keon CHAE
;
Keun Ho PARK
;
Young Youp KOH
;
Kyeong Ho YUN
;
Seok Kyu OH
;
Seung Jae JOO
;
Sun Ho HWANG
;
Jong Pil PARK
;
Jay Young RHEW
;
Su Hyun KIM
;
Jang Hyun CHO
;
Seung Uk LEE
;
Dong Goo KANG
Author Information
- Publication Type:Original Article
- From:Chonnam Medical Journal 2024;60(1):78-86
- CountryRepublic of Korea
- Language:EN
- Abstract: There are limited data on outcomes after implantation of everolimus-eluting stents (EES) in East Asian patients with small vessel coronary lesions. A total of 1,600 patients treated with XIENCE EES (Abbott Vascular, CA, USA) were divided into the small vessel group treated with one ≤2.5 mm stent (n=119) and the non-small vessel group treated with one ≥2.75 mm stent (n=933). The primary end point was a patient-oriented composite outcome (POCO), a composite of all-cause death, myocardial infarction (MI), and any repeat revascularization at 12 months. The key secondary end point was a device-oriented composite outcome (DOCO), a composite of cardiovascular death, target-vessel MI, and target lesion revascularization at 12 months. The small vessel group was more often female, hypertensive, less likely to present with ST-elevation MI, and more often treated for the left circumflex artery, whereas the non-small vessel group more often had type B2/C lesions, underwent intravascular ultrasound, and received unfractionated heparin. In the propensity matched cohort, the mean stent diameter was 2.5±0.0 mm and 3.1±0.4 mm in the small and non-small vessel groups, respectively. Propensity-adjusted POCO at 12 months was 6.0% in the small vessel group and 4.3% in the non-small vessel group (p=0.558). There was no significant difference in DOCO at 12 months (small vessel group: 4.3% and non-small vessel group: 1.7%, p=0.270).Outcomes of XIENCE EES for small vessel disease were comparable to those for non-small vessel disease at 12-month clinical follow-up in real-world Korean patients.
